Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. / Hansen, Stine Ninel; Westergaard, David; Thomsen, Mathilde Borg Houlberg; Vistesen, Mette Vixø; Do, Khoa Nguyen; Fogh, Louise; Belling, Kirstine G; Wang, Jun; Yang, Huanming; Gupta, Ramneek; Ditzel, Henrik Jørn; Moreira, José; Brünner, Nils; Stenvang, Jan; Rasmussen, Anne-Sofie Schrohl.

In: Tumor Biology, Vol. 36, No. 6, 2015, p. 4327-4338.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Hansen, SN, Westergaard, D, Thomsen, MBH, Vistesen, MV, Do, KN, Fogh, L, Belling, KG, Wang, J, Yang, H, Gupta, R, Ditzel, HJ, Moreira, J, Brünner, N, Stenvang, J & Rasmussen, A-SS 2015, 'Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways', Tumor Biology, vol. 36, no. 6, pp. 4327-4338. https://doi.org/10.1007/s13277-015-3072-4

APA

Hansen, S. N., Westergaard, D., Thomsen, M. B. H., Vistesen, M. V., Do, K. N., Fogh, L., Belling, K. G., Wang, J., Yang, H., Gupta, R., Ditzel, H. J., Moreira, J., Brünner, N., Stenvang, J., & Rasmussen, A-S. S. (2015). Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. Tumor Biology, 36(6), 4327-4338. https://doi.org/10.1007/s13277-015-3072-4

Vancouver

Hansen SN, Westergaard D, Thomsen MBH, Vistesen MV, Do KN, Fogh L et al. Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. Tumor Biology. 2015;36(6):4327-4338. https://doi.org/10.1007/s13277-015-3072-4

Author

Hansen, Stine Ninel ; Westergaard, David ; Thomsen, Mathilde Borg Houlberg ; Vistesen, Mette Vixø ; Do, Khoa Nguyen ; Fogh, Louise ; Belling, Kirstine G ; Wang, Jun ; Yang, Huanming ; Gupta, Ramneek ; Ditzel, Henrik Jørn ; Moreira, José ; Brünner, Nils ; Stenvang, Jan ; Rasmussen, Anne-Sofie Schrohl. / Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. In: Tumor Biology. 2015 ; Vol. 36, No. 6. pp. 4327-4338.

Bibtex

@article{6f752b324ecf46159fd92b1888bb5bbf,
title = "Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways",
abstract = "The microtubule-targeting taxanes are important in breast cancer therapy, but no predictive biomarkers have yet been identified with sufficient scientific evidence to allow clinical routine use. The purposes of the present study were to develop a cell-culture-based discovery platform for docetaxel resistance and thereby identify key molecular mechanisms and predictive molecular characteristics to docetaxel resistance. Two docetaxel-resistant cell lines, MCF7RES and MDARES, were generated from their respective parental cell lines MCF-7 and MDA-MB-231 by stepwise selection in docetaxel dose increments over 15 months. The cell lines were characterized regarding sensitivity to docetaxel and other chemotherapeutics and subjected to transcriptome-wide mRNA microarray profiling. MCF7RES and MDARES exhibited a biphasic growth inhibition pattern at increasing docetaxel concentrations. Gene expression analysis singled out ABCB1, which encodes permeability glycoprotein (Pgp), as the top upregulated gene in both MCF7RES and MDARES. Functional validation revealed Pgp as a key resistance mediator at low docetaxel concentrations (first-phase response), whereas additional resistance mechanisms appeared to be prominent at higher docetaxel concentrations (second-phase response). Additional resistance mechanisms were indicated by gene expression profiling, including genes in the interferon-inducible protein family in MCF7RES and cancer testis antigen family in MDARES. Also, upregulated expression of various ABC transporters, ECM-associated proteins, and lysosomal proteins was identified in both resistant cell lines. Finally, MCF7RES and MDARES presented with cross-resistance to epirubicin, but only MDARES showed cross-resistance to oxaliplatin. In conclusion, Pgp was identified as a key mediator of resistance to low docetaxel concentrations with other resistance mechanisms prominent at higher docetaxel concentrations. Supporting Pgp upregulation as one major mechanism of taxane resistance and cell-line-specific alterations as another, both MCF7RES and MDARES were cross-resistant to epirubicin (Pgp substrate), but only MDARES was cross-resistant to oxaliplatin (non-Pgp substrate).",
author = "Hansen, {Stine Ninel} and David Westergaard and Thomsen, {Mathilde Borg Houlberg} and Vistesen, {Mette Vix{\o}} and Do, {Khoa Nguyen} and Louise Fogh and Belling, {Kirstine G} and Jun Wang and Huanming Yang and Ramneek Gupta and Ditzel, {Henrik J{\o}rn} and Jos{\'e} Moreira and Nils Br{\"u}nner and Jan Stenvang and Rasmussen, {Anne-Sofie Schrohl}",
year = "2015",
doi = "10.1007/s13277-015-3072-4",
language = "English",
volume = "36",
pages = "4327--4338",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways

AU - Hansen, Stine Ninel

AU - Westergaard, David

AU - Thomsen, Mathilde Borg Houlberg

AU - Vistesen, Mette Vixø

AU - Do, Khoa Nguyen

AU - Fogh, Louise

AU - Belling, Kirstine G

AU - Wang, Jun

AU - Yang, Huanming

AU - Gupta, Ramneek

AU - Ditzel, Henrik Jørn

AU - Moreira, José

AU - Brünner, Nils

AU - Stenvang, Jan

AU - Rasmussen, Anne-Sofie Schrohl

PY - 2015

Y1 - 2015

N2 - The microtubule-targeting taxanes are important in breast cancer therapy, but no predictive biomarkers have yet been identified with sufficient scientific evidence to allow clinical routine use. The purposes of the present study were to develop a cell-culture-based discovery platform for docetaxel resistance and thereby identify key molecular mechanisms and predictive molecular characteristics to docetaxel resistance. Two docetaxel-resistant cell lines, MCF7RES and MDARES, were generated from their respective parental cell lines MCF-7 and MDA-MB-231 by stepwise selection in docetaxel dose increments over 15 months. The cell lines were characterized regarding sensitivity to docetaxel and other chemotherapeutics and subjected to transcriptome-wide mRNA microarray profiling. MCF7RES and MDARES exhibited a biphasic growth inhibition pattern at increasing docetaxel concentrations. Gene expression analysis singled out ABCB1, which encodes permeability glycoprotein (Pgp), as the top upregulated gene in both MCF7RES and MDARES. Functional validation revealed Pgp as a key resistance mediator at low docetaxel concentrations (first-phase response), whereas additional resistance mechanisms appeared to be prominent at higher docetaxel concentrations (second-phase response). Additional resistance mechanisms were indicated by gene expression profiling, including genes in the interferon-inducible protein family in MCF7RES and cancer testis antigen family in MDARES. Also, upregulated expression of various ABC transporters, ECM-associated proteins, and lysosomal proteins was identified in both resistant cell lines. Finally, MCF7RES and MDARES presented with cross-resistance to epirubicin, but only MDARES showed cross-resistance to oxaliplatin. In conclusion, Pgp was identified as a key mediator of resistance to low docetaxel concentrations with other resistance mechanisms prominent at higher docetaxel concentrations. Supporting Pgp upregulation as one major mechanism of taxane resistance and cell-line-specific alterations as another, both MCF7RES and MDARES were cross-resistant to epirubicin (Pgp substrate), but only MDARES was cross-resistant to oxaliplatin (non-Pgp substrate).

AB - The microtubule-targeting taxanes are important in breast cancer therapy, but no predictive biomarkers have yet been identified with sufficient scientific evidence to allow clinical routine use. The purposes of the present study were to develop a cell-culture-based discovery platform for docetaxel resistance and thereby identify key molecular mechanisms and predictive molecular characteristics to docetaxel resistance. Two docetaxel-resistant cell lines, MCF7RES and MDARES, were generated from their respective parental cell lines MCF-7 and MDA-MB-231 by stepwise selection in docetaxel dose increments over 15 months. The cell lines were characterized regarding sensitivity to docetaxel and other chemotherapeutics and subjected to transcriptome-wide mRNA microarray profiling. MCF7RES and MDARES exhibited a biphasic growth inhibition pattern at increasing docetaxel concentrations. Gene expression analysis singled out ABCB1, which encodes permeability glycoprotein (Pgp), as the top upregulated gene in both MCF7RES and MDARES. Functional validation revealed Pgp as a key resistance mediator at low docetaxel concentrations (first-phase response), whereas additional resistance mechanisms appeared to be prominent at higher docetaxel concentrations (second-phase response). Additional resistance mechanisms were indicated by gene expression profiling, including genes in the interferon-inducible protein family in MCF7RES and cancer testis antigen family in MDARES. Also, upregulated expression of various ABC transporters, ECM-associated proteins, and lysosomal proteins was identified in both resistant cell lines. Finally, MCF7RES and MDARES presented with cross-resistance to epirubicin, but only MDARES showed cross-resistance to oxaliplatin. In conclusion, Pgp was identified as a key mediator of resistance to low docetaxel concentrations with other resistance mechanisms prominent at higher docetaxel concentrations. Supporting Pgp upregulation as one major mechanism of taxane resistance and cell-line-specific alterations as another, both MCF7RES and MDARES were cross-resistant to epirubicin (Pgp substrate), but only MDARES was cross-resistant to oxaliplatin (non-Pgp substrate).

U2 - 10.1007/s13277-015-3072-4

DO - 10.1007/s13277-015-3072-4

M3 - Journal article

C2 - 25596703

VL - 36

SP - 4327

EP - 4338

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 6

ER -

ID: 135227947